| Keywords: |
survival; cancer survival; survival analysis; clinical trial; drug tolerability; mortality; bevacizumab; cisplatin; fluorouracil; cancer risk; dose response; drug efficacy; multimodality cancer therapy; note; paclitaxel; adjuvant therapy; comparative study; chemotherapy, adjuvant; combined modality therapy; neoadjuvant therapy; radiotherapy, adjuvant; drug megadose; methodology; sensitivity and specificity; multiple cycle treatment; blood toxicity; esophagitis; editorial; pathology; cetuximab; risk assessment; radiation dose fractionation; adjuvant chemotherapy; esophagus resection; pleura effusion; esophagus cancer; pericardial effusion; eye toxicity; esophagus tumor; esophageal neoplasms; esophagectomy
|
